肝脏脂肪变性多基因风险评分可预测丙肝治愈后肝癌风险
本研究基于台湾精准医学计划纳入420例接受直接抗病毒药物治疗的丙肝成人患者,回顾性分析脂肪变性多基因风险评分(PRS-5)与肝癌发生的关联。结果显示PRS-5≥0.66组5年肝癌累积发生率高于PRS-5<0.66组(23.97% vs. 8.89%,p=0.014),PRS-5≥0.66、体重指数>24 kg/m2及Fibrosis-4指数>3.25均与肝癌发生独立相关。
要点
- PRS-5≥0.66与丙肝治愈后肝癌风险独立相关(aSHR 3.59)。
- 体重指数>24 kg/m2及Fibrosis-4指数>3.25亦为独立危险因素。
- PRS-5在非肝硬化及Fibrosis-4指数<3.25亚组中仍有预测价值。
核心结论
- PRS-5与丙肝病毒清除后肝癌风险独立相关,支持其用于个体化肝癌监测策略。
研究设计与样本
- 回顾性队列研究,利用台湾精准医学倡议数据,纳入420例接受直接抗病毒药物治疗的丙肝成人患者,中位年龄67.0岁,46.9%为男性。
主要发现
- PRS-5≥0.66组5年肝癌累积发生率为23.97%(95%CI 7.15%-40.79%),高于PRS-5<0.66组的8.89%(95%CI 5.56%-12.23%),p=0.014。
- 多变量回归中,PRS-5≥0.66与肝癌发生的aSHR为3.59(95%CI 1.69-7.63,p<0.001)。
- 体重指数>24 kg/m2的aSHR为2.68(95%CI 1.24-5.78,p=0.012)。
- Fibrosis-4指数>3.25的aSHR为4.58(95%CI 2.20-9.53,p<0.001)。
- 亚组分析显示PRS-5在包括Fibrosis-4指数<3.25和非肝硬化在内的几乎所有亚组中均有预测价值。
临床怎么用
- 对于接受直接抗病毒药物治疗的丙肝患者,可考虑检测PRS-5以辅助分层肝癌监测策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Genetic predisposition to hepatic steatosis may increase hepatocellular carcinoma (HCC) risk after hepatitis C virus (HCV) eradication in cirrhotic patients; however, its impact on broader patient populations remains unexplored. We aimed to evaluate the association of steatosis-polygenic risk score (PRS) with HCC following direct-acting antiviral (DAA) therapy. METHODS: This retrospective cohort study utilised data from the Taiwan Precision Medicine Initiative, including adults treated with DAAs for HCV. Patients with treatment failure, hepatitis B virus co-infection, significant alcohol use, or HCC diagnosis prior to sustained virological response at 24 weeks were excluded. All participants underwent genotyping, with PRS-5 being used to quantify genetic risk. We evaluated the association between PRS-5 and the risk of incident HCC using restricted cubic spline analysis with Cox proportional hazards models. RESULTS: The cohort included 420 patients (median age 67.0 years; 46.9% male). The 5-year cumulative incidence of HCC in PRS-5 ≥ 0.66 group was higher than PRS-5 < 0.66 group (23.97%, 95% confidence interval (CI) 7.15%-40.79% vs. 8.89%, 95% CI 5.56%-12.23%; p = 0.014). In multivariable regression, PRS-5 ≥ 0.66 (aSHR 3.59, 95% CI 1.69-7.63; p < 0.001), body weight index > 24 kg/m2 (aSHR 2.68, 95% CI 1.24-5.78; p = 0.012), and Fibrosis-4 index > 3.25 (aSHR 4.58, 95% CI 2.20-9.53; p < 0.001) were independently associated with HCC occurrence. Subgroup analysis supported the predictive value of PRS-5 in almost all patient subgroups, including Fibrosis-4 index < 3.25 and non-cirrhosis. CONCLUSIONS: PRS-5 is independently associated with increased HCC risk after HCV eradication, supporting its role in personalised HCC surveillance strategies.
引用
- Lin YS, Lin YC, Chen YY, et al. Liver Steatosis-Related Polygenic Risk Score Predicts Hepatocellular Carcinoma Risk After Hepatitis C Virus Eradication. Aliment Pharmacol Ther. 2026. PMID: 41655131. doi:10.1111/apt.70566
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。